A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Clinical trial NCT06041802 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06041802
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-20
- Primary completion
- 2028-03-31
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.